← brief for 2026-11-02 · Slowing decline

Semaglutide and Cardiovascular Death: a Systematic Review and Meta-Analysis Cardioprotective Efficacy of Semaglutide.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This review combined data from many trials to check if semaglutide lowers the risk of dying from heart problems. It looked at people with type 2 diabetes, obesity, or kidney disease. The study found that semaglutide consistently reduces major heart events. This is important because heart disease is a top cause of death for people with kidney issues.

Who did this work

Marino G · Aquilani S · Di Fusco SA · Concistrè A · Nardi F · Gabrielli D · Imperoli G · Colivicchi F

Source

Article · PubMed, the drug frontier · 2026 Nov 2
https://pubmed.ncbi.nlm.nih.gov/42969445/